Leerink Partners started coverage on Mind Medicine (MindMed) in a report on Monday, October 14th. They issued an “outperform” rating and a $20.00 price objective for the company. Leerink ...
Oppenheimer analyst Francois Brisebois maintained a Buy rating on Mind Medicine (MNMD – Research Report) today and set a price target of $20.00. The company’s shares closed yesterday at $7.40.
NEW YORK, December 19, 2024--Mind Medicine (MindMed) Inc. (Nasdaq: MNMD), (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain ...
Bank of New York Mellon Corp boosted its position in shares of Mind Medicine (MindMed) by 472.7% in the second quarter. Bank of New York Mellon Corp now owns 246,208 shares of the company’s ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...